| Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy D Ciardiello, PP Vitiello, C Cardone, G Martini, T Troiani, E Martinelli, ... Cancer treatment reviews 76, 22-32, 2019 | 255 | 2019 |
| Clinical management of metastatic colorectal cancer in the era of precision medicine F Ciardiello, D Ciardiello, G Martini, S Napolitano, J Tabernero, ... CA: a cancer journal for clinicians 72 (4), 372-401, 2022 | 221 | 2022 |
| Clinical development of therapies targeting TGFβ: current knowledge and future perspectives D Ciardiello, E Elez, J Tabernero, J Seoane Annals of Oncology 31 (10), 1336-1349, 2020 | 178 | 2020 |
| Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives E Martinelli, D Ciardiello, G Martini, T Troiani, C Cardone, PP Vitiello, ... Annals of Oncology 31 (1), 30-40, 2020 | 144 | 2020 |
| Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition T Troiani, S Napolitano, D Vitagliano, F Morgillo, A Capasso, V Sforza, ... Clinical cancer research 20 (14), 3775-3786, 2014 | 118 | 2014 |
| Present and future of metastatic colorectal cancer treatment: a review of new candidate targets G Martini, T Troiani, C Cardone, P Vitiello, V Sforza, D Ciardiello, ... World journal of gastroenterology 23 (26), 4675, 2017 | 109 | 2017 |
| Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial E Martinelli, G Martini, V Famiglietti, T Troiani, S Napolitano, ... JAMA oncology 7 (10), 1529-1535, 2021 | 97 | 2021 |
| Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines PP Vitiello, C Cardone, G Martini, D Ciardiello, V Belli, N Matrone, G Barra, ... Journal of Experimental & Clinical Cancer Research 38, 1-12, 2019 | 74 | 2019 |
| EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer G Martini, C Cardone, PP Vitiello, V Belli, S Napolitano, T Troiani, ... Molecular Cancer Therapeutics 18 (4), 845-855, 2019 | 71 | 2019 |
| Implication of the Hedgehog pathway in hepatocellular carcinoma CM Della Corte, G Viscardi, F Papaccio, G Esposito, G Martini, ... World journal of gastroenterology 23 (24), 4330, 2017 | 64 | 2017 |
| AXL is an oncotarget in human colorectal cancer E Martinelli, G Martini, C Cardone, T Troiani, G Liguori, D Vitagliano, ... Oncotarget 6 (27), 23281, 2015 | 64 | 2015 |
| Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer G Martini, R Dienstmann, J Ros, I Baraibar, JL Cuadra-Urteaga, F Salva, ... Therapeutic Advances in Medical Oncology 12, 1758835920936089, 2020 | 52 | 2020 |
| Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The … Y Kagawa, E Elez, J García-Foncillas, H Bando, H Taniguchi, A Vivancos, ... Clinical Cancer Research 27 (9), 2515-2522, 2021 | 46 | 2021 |
| BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer J Ros, I Baraibar, E Sardo, N Mulet, F Salvà, G Argilés, G Martini, ... Therapeutic advances in medical oncology 13, 1758835921992974, 2021 | 43 | 2021 |
| Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations EF Giunta, V De Falco, S Napolitano, G Argenziano, G Brancaccio, ... Therapeutic Advances in Medical Oncology 12, 1758835920925219, 2020 | 41 | 2020 |
| Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience PP Vitiello, V De Falco, EF Giunta, D Ciardiello, C Cardone, P Vitale, ... Cancers 11 (10), 1504, 2019 | 40 | 2019 |
| Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed? G Martini, D Ciardiello, PP Vitiello, S Napolitano, C Cardone, A Cuomo, ... Cancer Treatment Reviews 86, 102023, 2020 | 39 | 2020 |
| Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case E Martinelli, T Troiani, V Sforza, G Martini, C Cardone, PP Vitiello, ... ESMO open 3 (1), e000299, 2018 | 37 | 2018 |
| Biomarker-guided anti-EGFR rechallenge therapy in metastatic colorectal cancer D Ciardiello, G Martini, V Famiglietti, S Napolitano, V De Falco, T Troiani, ... Cancers 13 (8), 1941, 2021 | 33 | 2021 |
| AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer C Cardone, B Blauensteiner, V Moreno-Viedma, G Martini, V Simeon, ... European Journal of Cancer 138, 1-10, 2020 | 29 | 2020 |
